Rodolphe Herve Sells 1,207 Shares of Palomar (NASDAQ:PLMR) Stock

Palomar Holdings, Inc. (NASDAQ:PLMR) COO Rodolphe Herve sold 1,207 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $135.35, for a total value of $163,367.45. Following the sale, the chief operating officer owned 3,548 shares of the company’s stock, valued at approximately $480,221.80. This represents a 25.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Palomar Trading Down 1.6%

Shares of NASDAQ:PLMR opened at $134.00 on Thursday. Palomar Holdings, Inc. has a 12-month low of $100.81 and a 12-month high of $147.62. The business’s fifty day simple moving average is $125.68 and its 200-day simple moving average is $123.60. The company has a market capitalization of $3.55 billion, a PE ratio of 18.01 and a beta of 0.40. The company has a current ratio of 0.49, a quick ratio of 0.49 and a debt-to-equity ratio of 0.31.

Palomar (NASDAQ:PLMR) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $2.36 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.17. Palomar had a return on equity of 23.62% and a net margin of 18.61%.The firm had revenue of $314.42 million during the quarter, compared to analysts’ expectations of $621.52 million. During the same period in the prior year, the business posted $1.76 EPS. As a group, equities research analysts predict that Palomar Holdings, Inc. will post 8.9 earnings per share for the current fiscal year.

Palomar Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 2nd. Shareholders of record on Wednesday, August 19th will be given a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend is Wednesday, August 19th.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of Palomar from $150.00 to $167.00 and gave the company an “overweight” rating in a research note on Monday, July 20th. Weiss Ratings raised Palomar from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 18th. Evercore set a $152.00 target price on Palomar in a research report on Friday, July 10th. Keefe, Bruyette & Woods raised their price target on Palomar from $162.00 to $166.00 and gave the stock an “outperform” rating in a report on Wednesday, July 8th. Finally, Zacks Research lowered Palomar from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 15th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Palomar presently has an average rating of “Moderate Buy” and a consensus target price of $162.50.

Palomar News Summary

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Palomar reported second-quarter EPS of $2.36, surpassing the $2.19 consensus estimate and rising from $1.76 a year earlier. Results benefited from strong premium growth and higher investment income, while return on equity was 22.62% and net margin was 20.11%. Palomar Q2 earnings beat
• Positive Sentiment: Zacks Research modestly raised its fiscal 2027 EPS forecast to $9.70 from $9.66 and increased its Q1 2027 estimate to $2.22 from $2.18, suggesting some confidence in near-term earnings momentum. Palomar analyst estimates
• Neutral Sentiment: Palomar declared a quarterly dividend of $0.45 per share, equivalent to $1.80 annually and a 1.3% yield. The dividend is payable September 2 to shareholders of record August 19. Palomar dividend announcement
• Neutral Sentiment: COO Rodolphe Herve sold 1,207 shares for approximately $163,367 to cover tax withholding tied to vested equity awards. Because the filing identified a tax-related purpose, the transaction provides limited insight into management’s outlook. Palomar SEC insider filing
• Negative Sentiment: Higher losses and expenses pressured underwriting margins, tempering the benefit of premium and investment-income growth. Reported revenue of $314.42 million was also below the approximately $621.5 million expectation cited in earnings coverage, creating concern about the quality and sustainability of growth. Palomar Q2 key metrics
• Negative Sentiment: Zacks cut its Q2 2028 EPS estimate to $2.12 from $2.26 and its fiscal 2028 forecast to $10.45 from $10.62, while maintaining a “Hold” rating. These revisions may be weighing on the stock despite the current-quarter earnings beat. Palomar revised earnings estimates

Hedge Funds Weigh In On Palomar

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PLMR. Geneos Wealth Management Inc. purchased a new position in shares of Palomar in the fourth quarter worth about $32,000. Kestra Advisory Services LLC purchased a new stake in Palomar in the fourth quarter valued at approximately $33,000. Rockefeller Capital Management L.P. increased its holdings in Palomar by 81.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company’s stock worth $40,000 after buying an additional 132 shares during the period. Frazier Financial Advisors LLC purchased a new position in Palomar during the 4th quarter worth approximately $54,000. Finally, Parallel Advisors LLC lifted its stake in Palomar by 638.3% during the 1st quarter. Parallel Advisors LLC now owns 443 shares of the company’s stock valued at $53,000 after acquiring an additional 383 shares during the period. Hedge funds and other institutional investors own 90.25% of the company’s stock.

About Palomar

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.